<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37510774</PMID><DateRevised><Year>2023</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2077-0383</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>14</Issue><PubDate><Year>2023</Year><Month>Jul</Month><Day>13</Day></PubDate></JournalIssue><Title>Journal of clinical medicine</Title><ISOAbbreviation>J Clin Med</ISOAbbreviation></Journal><ArticleTitle>Statin Use in Relation to COVID-19 and Other Respiratory Infections: Muscle and Other Considerations.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">4659</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/jcm12144659</ELocationID><Abstract><AbstractText>Statins have been widely advocated for use in COVID-19 based on large favorable observational associations buttressed by theoretical expected benefits. However, past favorable associations of statins to pre-COVID-19 infection outcomes (also buttressed by theoretical benefits) were unsupported in meta-analysis of RCTs, RR = 1.00. Initial RCTs in COVID-19 appear to follow this trajectory. Healthy-user/tolerator effects and indication bias may explain these disparities. Moreover, cholesterol drops in proportion to infection severity, so less severely affected individuals may be selected for statin use, contributing to apparent favorable statin associations to outcomes. Cholesterol transports fat-soluble antioxidants and immune-protective vitamins. Statins impair mitochondrial function in those most reliant on coenzyme Q10 (a mevalonate pathway product also transported on cholesterol)-i.e., those with existing mitochondrial compromise, whom data suggest bear increased risks from both COVID-19 and from statins. Thus, statin risks of adverse outcomes are amplified in those patients at risk of poor COVID-19 outcomes-i.e., those in whom adjunctive statin therapy may most likely be given. High reported rates of rhabdomyolysis in hospitalized COVID-19 patients underscore the notion that statin-related risks as well as benefits must be considered. Advocacy for statins in COVID-19 should be suspended pending clear evidence of RCT benefits, with careful attention to risk modifiers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Golomb</LastName><ForeName>Beatrice A</ForeName><Initials>BA</Initials><Identifier Source="ORCID">0000-0002-4454-0485</Identifier><AffiliationInfo><Affiliation>Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Jun Hee</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Medicine, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langsjoen</LastName><ForeName>Peter H</ForeName><Initials>PH</Initials><Identifier Source="ORCID">0000-0002-3355-2114</Identifier><AffiliationInfo><Affiliation>Langjoen Cardiology Clinic, Tyler, TX 75701, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dinkeloo</LastName><ForeName>Eero</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Navy and Marine Corps Public Health Center, Portsmouth, VA 23704, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zemljic-Harpf</LastName><ForeName>Alice E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of California, San Diego, La Jolla, CA 92093, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Affairs San Diego Healthcare System, San Diego, CA 92093, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL063055</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RO1 HL63055-05</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>J Clin Med</MedlineTA><NlmUniqueID>101606588</NlmUniqueID><ISSNLinking>2077-0383</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">muscle</Keyword><Keyword MajorTopicYN="N">post-COVID syndrome</Keyword><Keyword MajorTopicYN="N">rhabdomyolysis</Keyword><Keyword MajorTopicYN="N">statin</Keyword></KeywordList><CoiStatement>Zemljic-Harpf reports grants from MSD. Golomb has inherited stock in statin manufacturing companies. Langsjoen, Dinkeloo, and Han have no conflict of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>11</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>11</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>29</Day><Hour>1</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37510774</ArticleId><ArticleId IdType="pmc">PMC10380486</ArticleId><ArticleId IdType="doi">10.3390/jcm12144659</ArticleId><ArticleId IdType="pii">jcm12144659</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rationale for Consideration of Statins for COVID-19 Patients.  [(accessed on 4 October 2020)].  Available online:  https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/covid-19_domID_statin.pdf.</Citation></Reference><Reference><Citation>Ridker P.M., Danielson E., Fonseca F.A., Genest J., Gotto A.M., Jr., Kastelein J.J., Koenig W., Libby P., Lorenzatti A.J., MacFadyen J.G., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 2008;359:2195&#x2013;2207. doi: 10.1056/NEJMoa0807646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0807646</ArticleId><ArticleId IdType="pubmed">18997196</ArticleId></ArticleIdList></Reference><Reference><Citation>Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383&#x2013;1389.</Citation><ArticleIdList><ArticleId IdType="pubmed">7968073</ArticleId></ArticleIdList></Reference><Reference><Citation>Long B., Brady W.J., Koyfman A., Gottlieb M. Cardiovascular complications in COVID-19. Am. J. Emerg. Med. 2020;38:1504&#x2013;1507. doi: 10.1016/j.ajem.2020.04.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2020.04.048</ArticleId><ArticleId IdType="pmc">PMC7165109</ArticleId><ArticleId IdType="pubmed">32317203</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiner Z., Hatamipour M., Banach M., Pirro M., Al-Rasadi K., Jamialahmadi T., Radenkovic D., Montecucco F., Sahebkar A. Statins and the COVID-19 main protease: In silico evidence on direct interaction. Arch. Med. Sci. 2020;16:490&#x2013;496. doi: 10.5114/aoms.2020.94655.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/aoms.2020.94655</ArticleId><ArticleId IdType="pmc">PMC7212226</ArticleId><ArticleId IdType="pubmed">32399094</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas M.C. Complement in autoimmune inflammatory myopathies, the role of myositis-associated antibodies, COVID-19 associations, and muscle amyloid deposits. Expert Rev. Clin. Immunol. 2022;18:413&#x2013;423. doi: 10.1080/1744666X.2022.2054803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2022.2054803</ArticleId><ArticleId IdType="pubmed">35323101</ArticleId></ArticleIdList></Reference><Reference><Citation>Veyseh M., Koyoda S., Ayesha B. COVID-19 IgG-related autoimmune inflammatory necrotizing myositis. BMJ Case Rep. 2021;14:e239457. doi: 10.1136/bcr-2020-239457.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2020-239457</ArticleId><ArticleId IdType="pmc">PMC8051403</ArticleId><ArticleId IdType="pubmed">33849864</ArticleId></ArticleIdList></Reference><Reference><Citation>De Marco G., Giryes S., Williams K., Alcorn N., Slade M., Fitton J., Nizam S., Smithson G., Iqbal K., Tran G., et al. A Large Cluster of New Onset Autoimmune Myositis in the Yorkshire Region Following SARS-CoV-2 Vaccination. Vaccines. 2022;10:1184. doi: 10.3390/vaccines10081184.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10081184</ArticleId><ArticleId IdType="pmc">PMC9331977</ArticleId><ArticleId IdType="pubmed">35893834</ArticleId></ArticleIdList></Reference><Reference><Citation>Loghman M., Rahmanian E., Alikhani M., Saffar H., Beikmohamadi Hezaveh S., Nekooeian M., Shahriarirad R., Faezi S.T. Necrotizing autoimmune myositis following coronavirus disease 2019 infection: A case report. J. Med. Case Rep. 2022;16:488. doi: 10.1186/s13256-022-03680-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13256-022-03680-5</ArticleId><ArticleId IdType="pmc">PMC9793820</ArticleId><ArticleId IdType="pubmed">36575546</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemati M., Srai M., Rudrangi R. Statin-Induced Autoimmune Myopathy. Cureus. 2021;13:e13576. doi: 10.7759/cureus.13576.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.13576</ArticleId><ArticleId IdType="pmc">PMC8007198</ArticleId><ArticleId IdType="pubmed">33815984</ArticleId></ArticleIdList></Reference><Reference><Citation>Treppo E., Infantino M., Benucci M., Ravagnani V., Palterer B., Fabris M., Tomietto P., Manfredi M., Giudizi M.G., Ligobbi F., et al. Efficacy and Safety of High-Dose Immunoglobulin-Based Regimen in Statin-Associated Autoimmune Myopathy: A Multi-Center and Multi-Disciplinary Retrospective Study. J. Clin. Med. 2020;9:3454. doi: 10.3390/jcm9113454.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9113454</ArticleId><ArticleId IdType="pmc">PMC7692610</ArticleId><ArticleId IdType="pubmed">33121112</ArticleId></ArticleIdList></Reference><Reference><Citation>Troyanov Y., Landon-Cardinal O., Fritzler M.J., Ferreira J., Targoff I.N., Rich E., Goulet M., Goulet J.R., Bourre-Tessier J., Robitaille Y., et al. Atorvastatin-induced necrotizing autoimmune myositis: An emerging dominant entity in patients with autoimmune myositis presenting with a pure polymyositis phenotype. Medicine. 2017;96:e5694. doi: 10.1097/MD.0000000000005694.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000005694</ArticleId><ArticleId IdType="pmc">PMC5279076</ArticleId><ArticleId IdType="pubmed">28099331</ArticleId></ArticleIdList></Reference><Reference><Citation>Qasim Agha O., Kaur S., Vijayavel N. Statin-induced necrotising autoimmune myopathy and autoimmune hepatitis presenting with dysphagia. BMJ Case Rep. 2020;13:e232391. doi: 10.1136/bcr-2019-232391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr-2019-232391</ArticleId><ArticleId IdType="pmc">PMC7021121</ArticleId><ArticleId IdType="pubmed">32029513</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajmal M., Singh A., Kubba S., Hershman M., Acharya T. Statin-Induced Triad of Autoimmune Myocarditis, Myositis, and Transaminitis. Case Rep. Cardiol. 2021;2021:6660362. doi: 10.1155/2021/6660362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/6660362</ArticleId><ArticleId IdType="pmc">PMC8052178</ArticleId><ArticleId IdType="pubmed">33898067</ArticleId></ArticleIdList></Reference><Reference><Citation>Frasson E., Simonetto M., Bertolasi L., Caneve G., Vilotti C., Ruzza G., Perelli A., Piccinno M.G., Monaco S. Statin-associated necrotizing autoimmune myopathy with concurrent myasthenia gravis. Clin. Case Rep. 2021;9:e03925. doi: 10.1002/ccr3.3925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccr3.3925</ArticleId><ArticleId IdType="pmc">PMC8117815</ArticleId><ArticleId IdType="pubmed">34026125</ArticleId></ArticleIdList></Reference><Reference><Citation>Parikh P., Onuorah N., Vashisht P. A rare overlap of statin-induced anti-3-hydroxy-3-methyl-glutaryl-coenzyme A necrotizing autoimmune myositis and dermatomyositis. Rheumatol. Adv. Pract. 2021;5:rkab064. doi: 10.1093/rap/rkab064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rap/rkab064</ArticleId><ArticleId IdType="pmc">PMC8435662</ArticleId><ArticleId IdType="pubmed">34527856</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff D., Nee S., Hickey N.S., Marschollek M. Risk factors for Covid-19 severity and fatality: A structured literature review. Infection. 2021;49:15&#x2013;28. doi: 10.1007/s15010-020-01509-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-020-01509-1</ArticleId><ArticleId IdType="pmc">PMC7453858</ArticleId><ArticleId IdType="pubmed">32860214</ArticleId></ArticleIdList></Reference><Reference><Citation>Golomb B.A., Evans M.A., Dimsdale J.E., White H.L. Effects of statins on energy and fatigue with exertion: Results from a randomized controlled trial. Arch. Intern. Med. 2012;172:1180&#x2013;1182. doi: 10.1001/archinternmed.2012.2171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinternmed.2012.2171</ArticleId><ArticleId IdType="pmc">PMC4285455</ArticleId><ArticleId IdType="pubmed">22688574</ArticleId></ArticleIdList></Reference><Reference><Citation>Golomb B.A., Koperski S. Who becomes weak on statins? Effect modification exposed in a RCT by risk factor compounding. Circulation. 2013;127:AP072. doi: 10.1161/circ.127.suppl_12.AP072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circ.127.suppl_12.AP072</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans M.A., Golomb B.A. Statin-associated adverse cognitive effects: Survey results from 171 patients. Pharmacotherapy. 2009;29:800&#x2013;811. doi: 10.1592/phco.29.7.800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1592/phco.29.7.800</ArticleId><ArticleId IdType="pubmed">19558254</ArticleId></ArticleIdList></Reference><Reference><Citation>Cham S., Evans M.A., Denenberg J.O., Golomb B.A. Statin-associated muscle-related adverse effects: A case series of 354 patients. Pharmacotherapy. 2010;30:541&#x2013;553. doi: 10.1592/phco.30.6.541.</Citation><ArticleIdList><ArticleId IdType="doi">10.1592/phco.30.6.541</ArticleId><ArticleId IdType="pmc">PMC4729295</ArticleId><ArticleId IdType="pubmed">20500044</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares M.N., Eggelbusch M., Naddaf E., Gerrits K.H.L., van der Schaaf M., van den Borst B., Wiersinga W.J., van Vugt M., Weijs P.J.M., Murray A.J., et al. Skeletal muscle alterations in patients with acute Covid-19 and post-acute sequelae of Covid-19. J. Cachexia Sarcopenia Muscle. 2022;13:11&#x2013;22. doi: 10.1002/jcsm.12896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcsm.12896</ArticleId><ArticleId IdType="pmc">PMC8818659</ArticleId><ArticleId IdType="pubmed">34997689</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-de-Las-Penas C., Palacios-Cena D., Gomez-Mayordomo V., Palacios-Cena M., Rodriguez-Jimenez J., de-la-Llave-Rincon A.I., Velasco-Arribas M., Fuensalida-Novo S., Ambite-Quesada S., Guijarro C., et al. Fatigue and Dyspnoea as Main Persistent Post-COVID-19 Symptoms in Previously Hospitalized Patients: Related Functional Limitations and Disability. Respiration. 2022;101:132&#x2013;141. doi: 10.1159/000518854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000518854</ArticleId><ArticleId IdType="pmc">PMC8678253</ArticleId><ArticleId IdType="pubmed">34569550</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu Q., Paulose-Ram R., Burt V.L., Kit B.K. NCHS Data Brief. United States National Center for Health Statistics; Hyattsville, MD, USA: 2014. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003&#x2013;2012; pp. 1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25536410</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcazar-Fabra M., Trevisson E., Brea-Calvo G. Clinical syndromes associated with Coenzyme Q10 deficiency. Essays Biochem. 2018;62:377&#x2013;398. doi: 10.1042/EBC20170107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/EBC20170107</ArticleId><ArticleId IdType="pubmed">30030365</ArticleId></ArticleIdList></Reference><Reference><Citation>Navas P., Cascajo M.V., Alcazar-Fabra M., Hernandez-Camacho J.D., Sanchez-Cuesta A., Rodriguez A.B.C., Ballesteros-Simarro M., Arroyo-Luque A., Rodriguez-Aguilera J.C., Fernandez-Ayala D.J.M., et al. Secondary CoQ10 deficiency, bioenergetics unbalance in disease and aging. Biofactors. 2021;47:551&#x2013;569. doi: 10.1002/biof.1733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.1733</ArticleId><ArticleId IdType="pubmed">33878238</ArticleId></ArticleIdList></Reference><Reference><Citation>Littarru G.P., Tiano L. Bioenergetic and antioxidant properties of coenzyme Q10: Recent developments. Mol. Biotechnol. 2007;37:31&#x2013;37. doi: 10.1007/s12033-007-0052-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12033-007-0052-y</ArticleId><ArticleId IdType="pubmed">17914161</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortensen S.A., Rosenfeldt F., Kumar A., Dolliner P., Filipiak K.J., Pella D., Alehagen U., Steurer G., Littarru G.P. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: Results from Q-SYMBIO: A randomized double-blind trial. JACC Heart Fail. 2014;2:641&#x2013;649. doi: 10.1016/j.jchf.2014.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jchf.2014.06.008</ArticleId><ArticleId IdType="pubmed">25282031</ArticleId></ArticleIdList></Reference><Reference><Citation>Sunesen V.H., Weber C., Holmer G. Lipophilic antioxidants and polyunsaturated fatty acids in lipoprotein classes: Distribution and interaction. Eur. J. Clin. Nutr. 2001;55:115&#x2013;123. doi: 10.1038/sj.ejcn.1601127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.ejcn.1601127</ArticleId><ArticleId IdType="pubmed">11305624</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbiroli B., Frassineti C., Martinelli P., Iotti S., Lodi R., Cortelli P., Montagna P. Coenzyme Q10 improves mitochondrial respiration in patients with mitochondrial cytopathies. An in vivo study on brain and skeletal muscle by phosphorous magnetic resonance spectroscopy. Cell Mol. Biol. 1997;43:741&#x2013;749.</Citation><ArticleIdList><ArticleId IdType="pubmed">9298596</ArticleId></ArticleIdList></Reference><Reference><Citation>Golomb B.A., Evans M.A. Statin adverse effects: A review of the literature and evidence for a mitochondrial mechanism. Am. J. Cardiovasc. Drugs. 2008;8:373&#x2013;418. doi: 10.2165/0129784-200808060-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/0129784-200808060-00004</ArticleId><ArticleId IdType="pmc">PMC2849981</ArticleId><ArticleId IdType="pubmed">19159124</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y.H. Oxidative stress and mitochondrial DNA mutations in human aging. Proc. Soc. Exp. Biol. Med. 1998;217:53&#x2013;63. doi: 10.3181/00379727-217-44205.</Citation><ArticleIdList><ArticleId IdType="doi">10.3181/00379727-217-44205</ArticleId><ArticleId IdType="pubmed">9421207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.C., Wei Y.H. Role of Mitochondria in Human Aging. J. Biomed. Sci. 1997;4:319&#x2013;326. doi: 10.1007/BF02258357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF02258357</ArticleId><ArticleId IdType="pubmed">12386380</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward N.C., Watts G.F., Eckel R.H. Statin Toxicity. Circ. Res. 2019;124:328&#x2013;350. doi: 10.1161/CIRCRESAHA.118.312782.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.118.312782</ArticleId><ArticleId IdType="pubmed">30653440</ArticleId></ArticleIdList></Reference><Reference><Citation>Mollazadeh H., Tavana E., Fanni G., Bo S., Banach M., Pirro M., von Haehling S., Jamialahmadi T., Sahebkar A. Effects of statins on mitochondrial pathways. J. Cachexia Sarcopenia Muscle. 2021;12:237&#x2013;251. doi: 10.1002/jcsm.12654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcsm.12654</ArticleId><ArticleId IdType="pmc">PMC8061391</ArticleId><ArticleId IdType="pubmed">33511728</ArticleId></ArticleIdList></Reference><Reference><Citation>Haendeler J., Hoffmann J., Zeiher A.M., Dimmeler S. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: A novel vasculoprotective function of statins. Circulation. 2004;110:856&#x2013;861. doi: 10.1161/01.CIR.0000138743.09012.93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000138743.09012.93</ArticleId><ArticleId IdType="pubmed">15289372</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham D., Huynh N.N., Hamilton C.A., Beattie E., Smith R.A., Cocheme H.M., Murphy M.P., Dominiczak A.F. Mitochondria-targeted antioxidant MitoQ10 improves endothelial function and attenuates cardiac hypertrophy. Hypertension. 2009;54:322&#x2013;328. doi: 10.1161/HYPERTENSIONAHA.109.130351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/HYPERTENSIONAHA.109.130351</ArticleId><ArticleId IdType="pubmed">19581509</ArticleId></ArticleIdList></Reference><Reference><Citation>Alleva R., Tomasetti M., Andera L., Gellert N., Borghi B., Weber C., Murphy M.P., Neuzil J. Coenzyme Q blocks biochemical but not receptor-mediated apoptosis by increasing mitochondrial antioxidant protection. FEBS Lett. 2001;503:46&#x2013;50. doi: 10.1016/S0014-5793(01)02694-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(01)02694-1</ArticleId><ArticleId IdType="pubmed">11513852</ArticleId></ArticleIdList></Reference><Reference><Citation>Dave M., Attur M., Palmer G., Al-Mussawir H.E., Kennish L., Patel J., Abramson S.B. The antioxidant resveratrol protects against chondrocyte apoptosis via effects on mitochondrial polarization and ATP production. Arthritis Rheum. 2008;58:2786&#x2013;2797. doi: 10.1002/art.23799.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.23799</ArticleId><ArticleId IdType="pubmed">18759268</ArticleId></ArticleIdList></Reference><Reference><Citation>Reutelingsperger C.P., van Heerde W.L. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell. Mol. Life Sci. 1997;53:527&#x2013;532. doi: 10.1007/s000180050067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s000180050067</ArticleId><ArticleId IdType="pmc">PMC11147358</ArticleId><ArticleId IdType="pubmed">9230931</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlino M.V., Valenti N., Cesaro F., Costanzo A., Cristiano G., Guarino M., Sforza A. Predictors of Intensive Care Unit admission in patients with coronavirus disease 2019 (COVID-19) Monaldi. Arch. Chest Dis. 2020;90:1410. doi: 10.4081/monaldi.2020.1410.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/monaldi.2020.1410</ArticleId><ArticleId IdType="pubmed">32672430</ArticleId></ArticleIdList></Reference><Reference><Citation>Milenkovic M., Hadzibegovic A., Kovac M., Jovanovic B., Stanisavljevic J., Djikic M., Sijan D., Ladjevic N., Palibrk I., Djukanovic M., et al. D-dimer, CRP, PCT, and IL-6 Levels at Admission to ICU Can Predict In-Hospital Mortality in Patients with COVID-19 Pneumonia. Oxid. Med. Cell. Longev. 2022;2022:8997709. doi: 10.1155/2022/8997709.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/8997709</ArticleId><ArticleId IdType="pmc">PMC8884120</ArticleId><ArticleId IdType="pubmed">35237386</ArticleId></ArticleIdList></Reference><Reference><Citation>Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W., Gotto A.M., Jr. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. J. Am. Med. Assoc. 1998;279:1615&#x2013;1622. doi: 10.1001/jama.279.20.1615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.279.20.1615</ArticleId><ArticleId IdType="pubmed">9613910</ArticleId></ArticleIdList></Reference><Reference><Citation>Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) J. Am. Med. Assoc. 2002;288:2998&#x2013;3007. doi: 10.1001/jama.288.23.2998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.288.23.2998</ArticleId><ArticleId IdType="pubmed">12479764</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., Ford I., Gaw A., Hyland M., Jukema J.W., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet. 2002;360:1623&#x2013;1630. doi: 10.1016/S0140-6736(02)11600-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(02)11600-X</ArticleId><ArticleId IdType="pubmed">12457784</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore J.B., June C.H. Cytokine release syndrome in severe COVID-19. Science. 2020;368:473&#x2013;474. doi: 10.1126/science.abb8925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abb8925</ArticleId><ArticleId IdType="pubmed">32303591</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao L., Jin H., Wang M., Hu Y., Chen S., He Q., Chang J., Hong C., Zhou Y., Wang D., et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol. 2020;77:683&#x2013;690. doi: 10.1001/jamaneurol.2020.1127.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2020.1127</ArticleId><ArticleId IdType="pmc">PMC7149362</ArticleId><ArticleId IdType="pubmed">32275288</ArticleId></ArticleIdList></Reference><Reference><Citation>Rismanbaf A., Zarei S. Liver and Kidney Injuries in COVID-19 and Their Effects on Drug Therapy. Arch. Acad. Emerg. Med. 2020;8:e17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7075271</ArticleId><ArticleId IdType="pubmed">32185369</ArticleId></ArticleIdList></Reference><Reference><Citation>Golomb B.A. The starving cell: Metabolic syndrome as an adaptive process. Nat. Preced. 2011 doi: 10.1038/npre.2011.6535.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npre.2011.6535.1</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrilli C.M., Jones S.A., Yang J., Rajagopalan H., O&#x2019;Donnell L.F., Chernyak Y., Tobin K., Cerfolio R.J., Francois F., Horwitz L.I. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. medRxiv. 2020;369:m1966. doi: 10.1101/2020.04.08.20057794.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.08.20057794</ArticleId><ArticleId IdType="pmc">PMC7243801</ArticleId><ArticleId IdType="pubmed">32444366</ArticleId></ArticleIdList></Reference><Reference><Citation>Janda S., Young A., Fitzgerald J.M., Etminan M., Swiston J. The effect of statins on mortality from severe infections and sepsis: A systematic review and meta-analysis. J. Crit. Care. 2010;25:656.e7&#x2013;656.e22. doi: 10.1016/j.jcrc.2010.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2010.02.013</ArticleId><ArticleId IdType="pubmed">20413251</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Hoek H.L., Bos W.J.W., de Boer A., van de Garde E.M.W. Statins and prevention of infections: Systematic review and meta-analysis of data from large randomised placebo controlled trials. BMJ. 2011;343:10. doi: 10.1136/bmj.d7281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d7281</ArticleId><ArticleId IdType="pmc">PMC3226140</ArticleId><ArticleId IdType="pubmed">22127443</ArticleId></ArticleIdList></Reference><Reference><Citation>Golomb B.A. Do statins reduce the risk of infection? BMJ. 2011;343:d7134. doi: 10.1136/bmj.d7134.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.d7134</ArticleId><ArticleId IdType="pubmed">22127442</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniels L.B., Sitapati A.M., Zhang J., Zou J., Bui Q.M., Ren J., Longhurst C.A., Criqui M.H., Messer K. Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients. Am. J. Cardiol. 2020;136:149&#x2013;155. doi: 10.1016/j.amjcard.2020.09.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2020.09.012</ArticleId><ArticleId IdType="pmc">PMC7492151</ArticleId><ArticleId IdType="pubmed">32946859</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X.J., Qin J.J., Cheng X., Shen L., Zhao Y.C., Yuan Y., Lei F., Chen M.M., Yang H., Bai L., et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19. Cell Metab. 2020;32:176&#x2013;187.e174. doi: 10.1016/j.cmet.2020.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmet.2020.06.015</ArticleId><ArticleId IdType="pmc">PMC7311917</ArticleId><ArticleId IdType="pubmed">32592657</ArticleId></ArticleIdList></Reference><Reference><Citation>Israel A., Schaffer A., Cicurel A., Feldhamer I., Tal A., Cheng K., Sinha S., Schiff E., Lavie G., Ruppin E. Large population study identifies drugs associated with reduced COVID-19 severity. medRxiv. 2020 doi: 10.1101/2020.10.13.20211953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.10.13.20211953</ArticleId><ArticleId IdType="pmc">PMC8321549</ArticleId><ArticleId IdType="pubmed">34313216</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahedian-Azimi A., Mohammadi S.M., Heidari Beni F., Banach M., Guest P.C., Jamialahmadi T., Sahebkar A. Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: A systematic review and meta-analysis. Arch. Med. Sci. 2021;17:579&#x2013;595. doi: 10.5114/aoms/132950.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/aoms/132950</ArticleId><ArticleId IdType="pmc">PMC8130467</ArticleId><ArticleId IdType="pubmed">34025827</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C.C., Lee A.J., Su C.H., Huang C.Y., Islam M.M., Weng Y.C. Statin Use Is Associated with a Decreased Risk of Mortality among Patients with COVID-19. J. Clin. Med. 2021;10:1450. doi: 10.3390/jcm10071450.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10071450</ArticleId><ArticleId IdType="pmc">PMC8036545</ArticleId><ArticleId IdType="pubmed">33916281</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahedian-Azimi A., Mohammadi S.M., Banach M., Beni F.H., Guest P.C., Al-Rasadi K., Jamialahmadi T., Sahebkar A. Improved COVID-19 Outcomes following Statin Therapy: An Updated Systematic Review and Meta-analysis. Biomed. Res. Int. 2021;2021:1901772. doi: 10.1155/2021/1901772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/1901772</ArticleId><ArticleId IdType="pmc">PMC8463212</ArticleId><ArticleId IdType="pubmed">34568488</ArticleId></ArticleIdList></Reference><Reference><Citation>Kow C.S., Hasan S.S. Meta-analysis of Effect of Statins in Patients with COVID-19. Am. J. Cardiol. 2020;134:153&#x2013;155. doi: 10.1016/j.amjcard.2020.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2020.08.004</ArticleId><ArticleId IdType="pmc">PMC7419280</ArticleId><ArticleId IdType="pubmed">32891399</ArticleId></ArticleIdList></Reference><Reference><Citation>Kouhpeikar H., Khosaravizade Tabasi H., Khazir Z., Naghipour A., Mohammadi Moghadam H., Forouzanfar H., Abbasifard M., Kirichenko T.V., Reiner Z., Banach M., et al. Statin Use in COVID-19 Hospitalized Patients and Outcomes: A Retrospective Study. Front. Cardiovasc. Med. 2022;9:820260. doi: 10.3389/fcvm.2022.820260.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.820260</ArticleId><ArticleId IdType="pmc">PMC8907562</ArticleId><ArticleId IdType="pubmed">35282379</ArticleId></ArticleIdList></Reference><Reference><Citation>Memel Z.N., Lee J.J., Foulkes A.S., Chung R.T., Thaweethai T., Bloom P.P. Association of Statins and 28-Day Mortality Rates in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J. Infect. Dis. 2022;225:19&#x2013;29. doi: 10.1093/infdis/jiab539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab539</ArticleId><ArticleId IdType="pmc">PMC8586726</ArticleId><ArticleId IdType="pubmed">34665852</ArticleId></ArticleIdList></Reference><Reference><Citation>Feingold K.R., Brinton E.A., Grunfeld C. The Effect of Endocrine Disorders on Lipids and Lipoproteins. In: Feingold K.R., Anawalt B., Boyce A., Chrousos G., de Herder W.W., Dhatariya K., Dungan K., Hershman J.M., Hofland J., Kalra S., et al., editors. Endotext. MDText.com, Inc.; South Dartmouth, MA, USA: 2000.</Citation><ArticleIdList><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G., Greco M., Zanella A., Albano G., Antonelli M., Bellani G., Bonanomi E., Cabrini L., Carlesso E., Castelli G., et al. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern. Med. 2020;180:1345&#x2013;1355. doi: 10.1001/jamainternmed.2020.3539.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.3539</ArticleId><ArticleId IdType="pmc">PMC7364371</ArticleId><ArticleId IdType="pubmed">32667669</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal R., Banerjee M., Yadav U., Bhattacharjee S. Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis. Postgrad. Med. J. 2021;98:354&#x2013;359. doi: 10.1136/postgradmedj-2020-139172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/postgradmedj-2020-139172</ArticleId><ArticleId IdType="pubmed">33541927</ArticleId></ArticleIdList></Reference><Reference><Citation>De Spiegeleer A., Bronselaer A., Teo J.T., Byttebier G., De Tre G., Belmans L., Dobson R., Wynendaele E., Van De Wiele C., Vandaele F., et al. The Effects of ARBs, ACEis, and Statins on Clinical Outcomes of COVID-19 Infection Among Nursing Home Residents. J. Am. Med. Dir. Assoc. 2020;21:909&#x2013;914.e902. doi: 10.1016/j.jamda.2020.06.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamda.2020.06.018</ArticleId><ArticleId IdType="pmc">PMC7294267</ArticleId><ArticleId IdType="pubmed">32674818</ArticleId></ArticleIdList></Reference><Reference><Citation>Hariyanto T.I., Kurniawan A. Statin therapy did not improve the in-hospital outcome of coronavirus disease 2019 (COVID-19) infection. Diabetes Metab. Syndr. 2020;14:1613&#x2013;1615. doi: 10.1016/j.dsx.2020.08.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.08.023</ArticleId><ArticleId IdType="pmc">PMC7448951</ArticleId><ArticleId IdType="pubmed">32882643</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayeh S.K., Abbey E.J., Khalifa B.A.A., Nudotor R.D., Osei A.D., Chidambaram V., Osuji N., Khan S., Salia E.L., Oduwole M.O., et al. Statins use and COVID-19 outcomes in hospitalized patients. PLoS ONE. 2021;16:e0256899. doi: 10.1371/journal.pone.0256899.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0256899</ArticleId><ArticleId IdType="pmc">PMC8432819</ArticleId><ArticleId IdType="pubmed">34506533</ArticleId></ArticleIdList></Reference><Reference><Citation>Cariou B., Goronflot T., Rimbert A., Boullu S., Le May C., Moulin P., Pichelin M., Potier L., Smati S., Sultan A., et al. Routine use of statins and increased COVID-19 related mortality in inpatients with type 2 diabetes: Results from the CORONADO study. Diabetes Metab. 2021;47:101202. doi: 10.1016/j.diabet.2020.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabet.2020.10.001</ArticleId><ArticleId IdType="pmc">PMC7572108</ArticleId><ArticleId IdType="pubmed">33091555</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers A.J., Guan J., Trtchounian A., Hunninghake G.M., Kaimal R., Desai M., Kozikowski L.A., DeSouza L., Mogan S., Liu K.D., et al. Association of Elevated Plasma Interleukin-18 Level With Increased Mortality in a Clinical Trial of Statin Treatment for Acute Respiratory Distress Syndrome. Crit. Care Med. 2019;47:1089&#x2013;1096. doi: 10.1097/CCM.0000000000003816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000003816</ArticleId><ArticleId IdType="pmc">PMC6629502</ArticleId><ArticleId IdType="pubmed">31206358</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J.F., Washko G.R., Nakahira K., Hatabu H., Patel A.S., Fernandez I.E., Nishino M., Okajima Y., Yamashiro T., Ross J.C., et al. Statins and pulmonary fibrosis: The potential role of NLRP3 inflammasome activation. Am. J. Respir. Crit. Care Med. 2012;185:547&#x2013;556. doi: 10.1164/rccm.201108-1574OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201108-1574OC</ArticleId><ArticleId IdType="pmc">PMC3297101</ArticleId><ArticleId IdType="pubmed">22246178</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghafoori M., Saadati H., Taghavi M., Azimian A., Alesheikh P., Mohajerzadeh M.S., Behnamfar M., Pakzad M., Rameshrad M. Survival of the hospitalized patients with COVID-19 receiving atorvastatin: A randomized clinical trial. J. Med. Virol. 2022;94:3160&#x2013;3168. doi: 10.1002/jmv.27710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27710</ArticleId><ArticleId IdType="pmc">PMC9088596</ArticleId><ArticleId IdType="pubmed">35274326</ArticleId></ArticleIdList></Reference><Reference><Citation>Investigators I.-S. Atorvastatin versus placebo in patients with COVID-19 in intensive care: Randomized controlled trial. BMJ. 2022;376:e068407. doi: 10.1136/bmj-2021-068407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2021-068407</ArticleId><ArticleId IdType="pubmed">34996756</ArticleId></ArticleIdList></Reference><Reference><Citation>Davoodi L., Jafarpour H., Oladi Z., Zakariaei Z., Tabarestani M., Ahmadi B.M., Razavi A., Hessami A. Atorvastatin therapy in COVID-19 adult inpatients: A double-blind, randomized controlled trial. Int. J. Cardiol. Heart Vasc. 2021;36:100875. doi: 10.1016/j.ijcha.2021.100875.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcha.2021.100875</ArticleId><ArticleId IdType="pmc">PMC8437805</ArticleId><ArticleId IdType="pubmed">34541293</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghati N., Bhatnagar S., Mahendran M., Thakur A., Prasad K., Kumar D., Dwivedi T., Mani K., Tiwari P., Gupta R., et al. Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: A randomised clinical trial (RESIST trial) BMC Infect. Dis. 2022;22:606. doi: 10.1186/s12879-022-07570-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-022-07570-5</ArticleId><ArticleId IdType="pmc">PMC9270743</ArticleId><ArticleId IdType="pubmed">35810307</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaitan-Duarte H.G., Alvarez-Moreno C., Rincon-Rodriguez C.J., Yomayusa-Gonzalez N., Cortes J.A., Villar J.C., Bravo-Ojeda J.S., Garcia-Pena A., Adarme-Jaimes W., Rodriguez-Romero V.A., et al. Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: A pragmatic, open-label randomized trial. EClinicalMedicine. 2022;43:101242. doi: 10.1016/j.eclinm.2021.101242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101242</ArticleId><ArticleId IdType="pmc">PMC8686571</ArticleId><ArticleId IdType="pubmed">34957385</ArticleId></ArticleIdList></Reference><Reference><Citation>Xavier D.P., Chagas G.C.L., Gomes L.G.F., Ferri-Guerra J., Oquet R.E.H. Effects of statin therapy in hospitalized adult COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials. Einstein. 2023;21:eRW0351. doi: 10.31744/einstein_journal/2023RW0351.</Citation><ArticleIdList><ArticleId IdType="doi">10.31744/einstein_journal/2023RW0351</ArticleId><ArticleId IdType="pmc">PMC10247280</ArticleId><ArticleId IdType="pubmed">37341222</ArticleId></ArticleIdList></Reference><Reference><Citation>Marzolini C., Kuritzkes D.R., Marra F., Boyle A., Gibbons S., Flexner C., Pozniak A., Boffito M., Waters L., Burger D., et al. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications. Clin. Pharmacol. Ther. 2022;112:1191&#x2013;1200. doi: 10.1002/cpt.2646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.2646</ArticleId><ArticleId IdType="pmc">PMC9348462</ArticleId><ArticleId IdType="pubmed">35567754</ArticleId></ArticleIdList></Reference><Reference><Citation>Iribarren C., Dwyer J. Serum total cholesterol, stroke and all-cause mortality: Lessons from the Honolulu heart program. Nutr. Metab. Cardiovasc. Dis. 1997;7:169&#x2013;174.</Citation></Reference><Reference><Citation>Jacobs D., Blackburn H., Higgins M., Reed D., Iso H., McMillan G., Neaton J., Nelson J., Potter J., Rifkind B., et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation. 1992;86:1046&#x2013;1060. doi: 10.1161/01.CIR.86.3.1046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.86.3.1046</ArticleId><ArticleId IdType="pubmed">1355411</ArticleId></ArticleIdList></Reference><Reference><Citation>Neaton J.D., Wentworth D.N. Low serum cholesterol and risk of death from AIDS. AIDS. 1997;11:929&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pubmed">9189220</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu X., Chen D., Wu L., He G., Ye W. Low Serum Cholesterol Level among Patients with COVID-19 Infection in Wenzhou, China. Lancet. 2020 doi: 10.2139/ssrn.3544826.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.3544826</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi A., Masuda A., Sun M., Centonze V.E., Herman B. Oxidative stress-induced apoptosis is associated with alterations in mitochondrial caspase activity and Bcl-2-dependent alterations in mitochondrial pH (pHm) Brain Res. Bull. 2004;62:497&#x2013;504. doi: 10.1016/j.brainresbull.2003.07.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2003.07.009</ArticleId><ArticleId IdType="pubmed">15036564</ArticleId></ArticleIdList></Reference><Reference><Citation>Chidambaram V., Shanmugavel Geetha H., Kumar A., Majella M.G., Sivakumar R.K., Voruganti D., Mehta J.L., Karakousis P.C. Association of Lipid Levels With COVID-19 Infection, Disease Severity and Mortality: A Systematic Review and Meta-Analysis. Front. Cardiovasc. Med. 2022;9:862999. doi: 10.3389/fcvm.2022.862999.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.862999</ArticleId><ArticleId IdType="pmc">PMC8988060</ArticleId><ArticleId IdType="pubmed">35402531</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Kuraishy H.M., Hussien N.R., Al-Niemi M.S., Fahad E.H., Al-Buhadily A.K., Al-Gareeb A.I., Al-Hamash S.M., Tsagkaris C., Papadakis M., Alexiou A., et al. SARS-CoV-2 induced HDL dysfunction may affect the host&#x2019;s response to and recovery from COVID-19. Immun. Inflamm. Dis. 2023;11:e861. doi: 10.1002/iid3.861.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.861</ArticleId><ArticleId IdType="pmc">PMC10187021</ArticleId><ArticleId IdType="pubmed">37249296</ArticleId></ArticleIdList></Reference><Reference><Citation>Correa Y., Del Giudice R., Waldie S., Thepaut M., Micciula S., Gerelli Y., Moulin M., Delaunay C., Fieschi F., Pichler H., et al. High-Density Lipoprotein function is modulated by the SARS-CoV-2 spike protein in a lipid-type dependent manner. J. Colloid. Interface Sci. 2023;645:627&#x2013;638. doi: 10.1016/j.jcis.2023.04.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcis.2023.04.137</ArticleId><ArticleId IdType="pmc">PMC10147446</ArticleId><ArticleId IdType="pubmed">37167912</ArticleId></ArticleIdList></Reference><Reference><Citation>Parra S., Saballs M., DiNubile M., Feliu M., Iftimie S., Revuelta L., Pavon R., Avila A., Levinson S., Castro A. Low HDL-c levels at admission are associated with greater severity and worse clinical outcomes in patients with COVID-19 disease. Atheroscler. Plus. 2023;52:1&#x2013;8. doi: 10.1016/j.athplu.2023.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athplu.2023.01.002</ArticleId><ArticleId IdType="pmc">PMC9988188</ArticleId><ArticleId IdType="pubmed">36910513</ArticleId></ArticleIdList></Reference><Reference><Citation>Feingold K.R., Grunfeld C. The Effect of Inflammation and Infection on Lipids and Lipoproteins.  [(accessed on 7 July 2023)];2015  Available online:  https://www.ncbi.nlm.nih.gov/books/NBK326741/</Citation></Reference><Reference><Citation>Bjornson L.K., Kayden H.J., Miller E., Moshell A.N. The transport of alpha-tocopherol and beta-carotene in human blood. J. Lipid Res. 1976;17:343&#x2013;352. doi: 10.1016/S0022-2275(20)34917-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-2275(20)34917-8</ArticleId><ArticleId IdType="pubmed">181502</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez M.J. Serum concentrations and cellular uptake of vitamin E. Med. Hypotheses. 1990;32:107&#x2013;110. doi: 10.1016/0306-9877(90)90032-A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-9877(90)90032-A</ArticleId><ArticleId IdType="pubmed">2165554</ArticleId></ArticleIdList></Reference><Reference><Citation>Johansen K., Theorell H., Karlsson J., Diamant B., Folkers K. Coenzyme Q10, alpha-tocopherol and free cholesterol in HDL and LDL fractions. Ann. Med. 1991;23:649&#x2013;656. doi: 10.3109/07853899109148098.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/07853899109148098</ArticleId><ArticleId IdType="pubmed">1777220</ArticleId></ArticleIdList></Reference><Reference><Citation>Kokoglu E., Ulakoglu E. The transport of vitamin E in plasma and its correlation to plasma lipoproteins in non-insulin-dependent diabetes mellitus. Diabetes Res. Clin. Pract. 1991;14:175&#x2013;181. doi: 10.1016/0168-8227(91)90018-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0168-8227(91)90018-9</ArticleId><ArticleId IdType="pubmed">1778110</ArticleId></ArticleIdList></Reference><Reference><Citation>Littarru G.P., Langsjoen P. Coenzyme Q(10) and statins: Biochemical and clinical implications. Mitochondrion. 2007;7((Suppl. 1)):S168&#x2013;S174. doi: 10.1016/j.mito.2007.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2007.03.002</ArticleId><ArticleId IdType="pubmed">17482884</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho K.H., Kim J.R., Lee I.C., Kwon H.J. Native High-Density Lipoproteins (HDL) with Higher Paraoxonase Exerts a Potent Antiviral Effect against SARS-CoV-2 (COVID-19), While Glycated HDL Lost the Antiviral Activity. Antioxidants. 2021;10:209. doi: 10.3390/antiox10020209.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10020209</ArticleId><ArticleId IdType="pmc">PMC7912765</ArticleId><ArticleId IdType="pubmed">33535459</ArticleId></ArticleIdList></Reference><Reference><Citation>Blatter Garin M.C., Moren X., James R.W. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. J. Lipid Res. 2006;47:515&#x2013;520. doi: 10.1194/jlr.M500281-JLR200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1194/jlr.M500281-JLR200</ArticleId><ArticleId IdType="pubmed">16327022</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaouad L., Milochevitch C., Khalil A. PON1 paraoxonase activity is reduced during HDL oxidation and is an indicator of HDL antioxidant capacity. Free Radic Res. 2003;37:77&#x2013;83. doi: 10.1080/1071576021000036614.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1071576021000036614</ArticleId><ArticleId IdType="pubmed">12653220</ArticleId></ArticleIdList></Reference><Reference><Citation>Koren-Gluzer M., Aviram M., Meilin E., Hayek T. The antioxidant HDL-associated paraoxonase-1 (PON1) attenuates diabetes development and stimulates beta-cell insulin release. Atherosclerosis. 2011;219:510&#x2013;518. doi: 10.1016/j.atherosclerosis.2011.07.119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.atherosclerosis.2011.07.119</ArticleId><ArticleId IdType="pubmed">21862013</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhar M.B. Update on managing hypercholesterolemia. The new NCEP guidelines. AAOHN J. 2002;50:360&#x2013;364. doi: 10.1177/216507990205000808.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/216507990205000808</ArticleId><ArticleId IdType="pubmed">12227210</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasvold P., Thuresson M., Sundstr&#xf6;m J., Hammar N., Kjeldsen S.E., Johansson G., Holme I., Bodeg&#xe5;rd J. Association Between Paradoxical HDL Cholesterol Decrease and Risk of Major Adverse Cardiovascular Events in Patients Initiated on Statin Treatment in a Primary Care Setting. Clin. Drug Investig. 2016;36:225&#x2013;233. doi: 10.1007/s40261-015-0372-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40261-015-0372-9</ArticleId><ArticleId IdType="pmc">PMC4761013</ArticleId><ArticleId IdType="pubmed">26718960</ArticleId></ArticleIdList></Reference><Reference><Citation>Guirgis F.W., Donnelly J.P., Dodani S., Howard G., Safford M.M., Levitan E.B., Wang H.E. Cholesterol levels and long-term rates of community-acquired sepsis. Crit. Care. 2016;20:408. doi: 10.1186/s13054-016-1579-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1579-8</ArticleId><ArticleId IdType="pmc">PMC5180408</ArticleId><ArticleId IdType="pubmed">28010729</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinzinger H., Chehne F., Lupattelli G. Oxidation Injury in Patients Receiving HMG-CoA Reductase Inhibitors: Occurrence in Patients Without Enzyme Elevation or Myopathy. Drug Saf. 2002;25:877&#x2013;883. doi: 10.2165/00002018-200225120-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002018-200225120-00005</ArticleId><ArticleId IdType="pubmed">12241128</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinzinger H., Lupattelli G., Chehne F., Oguogho A., Furberg C.D. Isoprostane 8-epi-PGF2alpha is frequently increased in patients with muscle pain and/or CK-elevation after HMG-Co-enzyme-A-reductase inhibitor therapy. J. Clin. Pharm. Ther. 2001;26:303&#x2013;310. doi: 10.1046/j.1365-2710.2001.00360.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2710.2001.00360.x</ArticleId><ArticleId IdType="pubmed">11493374</ArticleId></ArticleIdList></Reference><Reference><Citation>Schalke B.B., Schmidt B., Toyka K., Hartung H.P. Pravastatin-associated inflammatory myopathy. N. Engl. J. Med. 1992;327:649&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">1640970</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuncova K., Sedlackova M., Vencovsky J., Mann H., Tomcik M., Wenchich L., Zamecnik J. Inflammatory myopathy associated with statins: Report of three cases. Mod. Rheumatol. 2014;24:366&#x2013;371. doi: 10.3109/14397595.2013.852848.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/14397595.2013.852848</ArticleId><ArticleId IdType="pubmed">24593216</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman K.B., Kraus C., Dimbil M., Golomb B.A. A Survey of the FDA&#x2019;s AERS Database Regarding Muscle and Tendon Adverse Events Linked to the Statin Drug Class. PLoS ONE. 2012;7:e42866. doi: 10.1371/journal.pone.0042866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0042866</ArticleId><ArticleId IdType="pmc">PMC3425581</ArticleId><ArticleId IdType="pubmed">22936996</ArticleId></ArticleIdList></Reference><Reference><Citation>Honarmand A., Sheybani F., Aflatoonian E., Saberinia A. COVID-19 patients at referral to hospital during the first peak of disease: Common clinical findings including myalgia and fatigue. Eur. J. Transl. Myol. 2022 doi: 10.4081/ejtm.2022.10731.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/ejtm.2022.10731</ArticleId><ArticleId IdType="pmc">PMC9580529</ArticleId><ArticleId IdType="pubmed">36036352</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda M., Kanda T. Peripheral Neuropathy and Myopathy Associated with COVID-19. Brain Nerve. 2022;74:867&#x2013;871. doi: 10.11477/mf.1416202140.</Citation><ArticleIdList><ArticleId IdType="doi">10.11477/mf.1416202140</ArticleId><ArticleId IdType="pubmed">35860933</ArticleId></ArticleIdList></Reference><Reference><Citation>Meacci E., Pierucci F., Garcia-Gil M. Skeletal Muscle and COVID-19: The Potential Involvement of Bioactive Sphingolipids. Biomedicines. 2022;10:1068. doi: 10.3390/biomedicines10051068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines10051068</ArticleId><ArticleId IdType="pmc">PMC9138286</ArticleId><ArticleId IdType="pubmed">35625805</ArticleId></ArticleIdList></Reference><Reference><Citation>Attaway A., Welch N., Dasarathy D., Amaya-Hughley J., Bellar A., Biehl M., Dugar S., Engelen M., Zein J., Dasarathy S. Acute skeletal muscle loss in SARS-CoV-2 infection contributes to poor clinical outcomes in COVID-19 patients. J. Cachexia Sarcopenia Muscle. 2022;13:2436&#x2013;2446. doi: 10.1002/jcsm.13052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcsm.13052</ArticleId><ArticleId IdType="pmc">PMC9350025</ArticleId><ArticleId IdType="pubmed">35851995</ArticleId></ArticleIdList></Reference><Reference><Citation>Filippetti L., Pace N., Louis J.S., Mandry D., Goehringer F., Rocher M.S., Jay N., Selton-Suty C., Hossu G., Huttin O., et al. Long-Lasting Myocardial and Skeletal Muscle Damage Evidenced by Serial CMR During the First Year in COVID-19 Patients From the First Wave. Front. Cardiovasc. Med. 2022;9:831580. doi: 10.3389/fcvm.2022.831580.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2022.831580</ArticleId><ArticleId IdType="pmc">PMC8959613</ArticleId><ArticleId IdType="pubmed">35355964</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouitbir J., Sanvee G.M., Panajatovic M.V., Singh F., Krahenbuhl S. Mechanisms of statin-associated skeletal muscle-associated symptoms. Pharmacol. Res. 2020;154:104201. doi: 10.1016/j.phrs.2019.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2019.03.010</ArticleId><ArticleId IdType="pubmed">30877064</ArticleId></ArticleIdList></Reference><Reference><Citation>Cros D., Palliyath S., DiMauro S., Ramirez C., Shamsnia M., Wizer B. Respiratory failure revealing mitochondrial myopathy in adults. Chest. 1992;101:824&#x2013;828. doi: 10.1378/chest.101.3.824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.101.3.824</ArticleId><ArticleId IdType="pubmed">1541151</ArticleId></ArticleIdList></Reference><Reference><Citation>Arena I.G., Pugliese A., Volta S., Toscano A., Musumeci O. Molecular Genetics Overview of Primary Mitochondrial Myopathies. J. Clin. Med. 2022;11:632. doi: 10.3390/jcm11030632.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11030632</ArticleId><ArticleId IdType="pmc">PMC8836969</ArticleId><ArticleId IdType="pubmed">35160083</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumbalova Z., Kucharska J., Palacka P., Rausova Z., Langsjoen P.H., Langsjoen A.M., Gvozdjakova A. Platelet mitochondrial function and endogenous coenzyme Q10 levels are reduced in patients after COVID-19. Bratisl. Lek. Listy. 2022;123:9&#x2013;15. doi: 10.4149/BLL_2022_002.</Citation><ArticleIdList><ArticleId IdType="doi">10.4149/BLL_2022_002</ArticleId><ArticleId IdType="pubmed">34967652</ArticleId></ArticleIdList></Reference><Reference><Citation>Langsjoen P.H., Langsjoen J.O., Langsjoen A.M., Rosenfeldt F. Statin-Associated Cardiomyopathy Responds to Statin Withdrawal and Administration of Coenzyme Q10. Perm. J. 2019;23:257. doi: 10.7812/TPP/18.257.</Citation><ArticleIdList><ArticleId IdType="doi">10.7812/TPP/18.257</ArticleId><ArticleId IdType="pmc">PMC6730959</ArticleId><ArticleId IdType="pubmed">31496499</ArticleId></ArticleIdList></Reference><Reference><Citation>Silver M.A., Langsjoen P.H., Szabo S., Patil H., Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. Am. J. Cardiol. 2004;94:1306&#x2013;1310. doi: 10.1016/j.amjcard.2004.07.121.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2004.07.121</ArticleId><ArticleId IdType="pubmed">15541254</ArticleId></ArticleIdList></Reference><Reference><Citation>Fried J.A., Ramasubbu K., Bhatt R., Topkara V.K., Clerkin K.J., Horn E., Rabbani L., Brodie D., Jain S.S., Kirtane A., et al. The Variety of Cardiovascular Presentations of COVID-19. Circulation. 2020;141:1930&#x2013;1936. doi: 10.1161/CIRCULATIONAHA.120.047164.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.047164</ArticleId><ArticleId IdType="pmc">PMC7314498</ArticleId><ArticleId IdType="pubmed">32243205</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerveri I., Fanfulla F., Zoia M.C., Manni R., Tartara A. Sleep disorders in neuromuscular diseases. Monaldi. Arch. Chest. Dis. 1993;48:318&#x2013;321.</Citation><ArticleIdList><ArticleId IdType="pubmed">8257973</ArticleId></ArticleIdList></Reference><Reference><Citation>Cham S., Gill K., Koperski S., Golomb B.A. Improvement in sleep apnoea associated with switch from simvastatin to pravastatin. BMJ Case Rep. 2009;2009:bcr05.2009.1875. doi: 10.1136/bcr.05.2009.1875.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bcr.05.2009.1875</ArticleId><ArticleId IdType="pmc">PMC3029510</ArticleId><ArticleId IdType="pubmed">21886657</ArticleId></ArticleIdList></Reference><Reference><Citation>Corda L., Redolfi S., Montemurro L.T., La Piana G.E., Bertella E., Tantucci C. Short- and long-term effects of CPAP on upper airway anatomy and collapsibility in OSAH. Sleep Breath. 2009;13:187&#x2013;193. doi: 10.1007/s11325-008-0219-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11325-008-0219-1</ArticleId><ArticleId IdType="pubmed">18815823</ArticleId></ArticleIdList></Reference><Reference><Citation>O-Brien R. Doctors are Improvising Coronavirus Treatments, Then Quickly Sharing Them. Wall Street Journal. Apr 9, 2020.</Citation></Reference><Reference><Citation>Elharrar X., Youssef T., Martinez M., Maulin L. Prone Positioning in Spontaneously Breathing Nonintubated COVID-19 Patient: A Pilot Study (ProCov)  [(accessed on 5 May 2020)]; Available online:  https://clinicaltrials.gov/ct2/show/NCT04344106.</Citation></Reference><Reference><Citation>Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab. Syndr. 2020;14:247&#x2013;250. doi: 10.1016/j.dsx.2020.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.dsx.2020.03.013</ArticleId><ArticleId IdType="pmc">PMC7102662</ArticleId><ArticleId IdType="pubmed">32247212</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavie L. Oxidative stress inflammation and endothelial dysfunction in obstructive sleep apnea. Front. Biosci. 2012;4:1391&#x2013;1403. doi: 10.2741/e469.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/e469</ArticleId><ArticleId IdType="pubmed">22201964</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco C.M., Lima A.M., Ataide L., Jr., Lins O.G., Castro C.M., Bezerra A.A., de Oliveira M.F., Oliveira J.R. Obstructive Sleep Apnea Severity Correlates with Cellular and Plasma Oxidative Stress Parameters and Affective Symptoms. J. Mol. Neurosci. 2012;47:300&#x2013;310. doi: 10.1007/s12031-012-9738-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12031-012-9738-0</ArticleId><ArticleId IdType="pubmed">22402994</ArticleId></ArticleIdList></Reference><Reference><Citation>Murri M., Garcia-Delgado R., Alcazar-Ramirez J., Fernandez de Rota L., Fernandez-Ramos A., Cardona F., Tinahones F.J. Continuous positive airway pressure therapy reduces oxidative stress markers and blood pressure in sleep apnea-hypopnea syndrome patients. Biol. Trace Elem. Res. 2011;143:1289&#x2013;1301. doi: 10.1007/s12011-011-8969-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12011-011-8969-1</ArticleId><ArticleId IdType="pubmed">21286851</ArticleId></ArticleIdList></Reference><Reference><Citation>Murri M., Alcazar-Ramirez J., Garrido-Sanchez L., Linde F., Alcaide J., Cardona F., Tinahones F.J. Oxidative stress and metabolic changes after continuous positive airway pressure treatment according to previous metabolic disorders in sleep apnea-hypopnea syndrome patients. Transl. Res. 2009;154:111&#x2013;121. doi: 10.1016/j.trsl.2009.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2009.06.001</ArticleId><ArticleId IdType="pubmed">19665687</ArticleId></ArticleIdList></Reference><Reference><Citation>Montiel V., Lobysheva I., Gerard L., Vermeersch M., Perez-Morga D., Castelein T., Mesland J.B., Hantson P., Collienne C., Gruson D., et al. Oxidative stress-induced endothelial dysfunction and decreased vascular nitric oxide in COVID-19 patients. EBioMedicine. 2022;77:103893. doi: 10.1016/j.ebiom.2022.103893.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103893</ArticleId><ArticleId IdType="pmc">PMC8865837</ArticleId><ArticleId IdType="pubmed">35219085</ArticleId></ArticleIdList></Reference><Reference><Citation>Passos F.R.S., Heimfarth L., Monteiro B.S., Correa C.B., Moura T.R., Araujo A.A.S., Martins-Filho P.R., Quintans-Junior L.J., Quintans J.S.S. Oxidative stress and inflammatory markers in patients with COVID-19: Potential role of RAGE, HMGB1, GFAP and COX-2 in disease severity. Int. Immunopharmacol. 2022;104:108502. doi: 10.1016/j.intimp.2021.108502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.108502</ArticleId><ArticleId IdType="pmc">PMC8730710</ArticleId><ArticleId IdType="pubmed">35063743</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyhanli E.S., Koyuncu I., Yasak I.H., Demir H.A., Temiz E. Asprosin and Oxidative Stress Level in COVID-19 Patients. Clin. Lab. 2022;68:35&#x2013;42. doi: 10.7754/Clin.Lab.2021.210423.</Citation><ArticleIdList><ArticleId IdType="doi">10.7754/Clin.Lab.2021.210423</ArticleId><ArticleId IdType="pubmed">35023691</ArticleId></ArticleIdList></Reference><Reference><Citation>Skesters A., Kustovs D., Lece A., Moreino E., Petrosina E., Rainsford K.D. Selenium, selenoprotein P, and oxidative stress levels in SARS-CoV-2 patients during illness and recovery. Inflammopharmacology. 2022;30:499&#x2013;503. doi: 10.1007/s10787-022-00925-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-022-00925-z</ArticleId><ArticleId IdType="pmc">PMC8853000</ArticleId><ArticleId IdType="pubmed">35157169</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk L.E., Tami A., Hillebrands J.L., den Dunnen W.F.A., de Borst M.H., van der Voort P.H.J., Bulthuis M.L.C., Veloo A.C.M., Wold K.I., Vincenti Gonzalez M.F., et al. Mild Coronavirus Disease 2019 (COVID-19) Is Marked by Systemic Oxidative Stress: A Pilot Study. Antioxidants. 2021;10:2022. doi: 10.3390/antiox10122022.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antiox10122022</ArticleId><ArticleId IdType="pmc">PMC8698810</ArticleId><ArticleId IdType="pubmed">34943125</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu N., Long H., Sun J., Li H., He Y., Wang Q., Pan K., Tong Y., Wang B., Wu Q., et al. New laboratory evidence for the association between endothelial dysfunction and COVID-19 disease progression. J. Med. Virol. 2022;94:3112&#x2013;3120. doi: 10.1002/jmv.27693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27693</ArticleId><ArticleId IdType="pmc">PMC9088409</ArticleId><ArticleId IdType="pubmed">35246853</ArticleId></ArticleIdList></Reference><Reference><Citation>Tessema B., Sack U., Konig B., Serebrovska Z., Egorov E. Effects of Intermittent Hypoxia in Training Regimes and in Obstructive Sleep Apnea on Aging Biomarkers and Age-Related Diseases: A Systematic Review. Front. Aging Neurosci. 2022;14:878278. doi: 10.3389/fnagi.2022.878278.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2022.878278</ArticleId><ArticleId IdType="pmc">PMC9168371</ArticleId><ArticleId IdType="pubmed">35677200</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou X., Zhai X., Ashraf M. Direct evidence that initial oxidative stress triggered by preconditioning contributes to second window of protection by endogenous antioxidant enzyme in myocytes. Circulation. 1996;93:1177&#x2013;1184. doi: 10.1161/01.CIR.93.6.1177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.93.6.1177</ArticleId><ArticleId IdType="pubmed">8653839</ArticleId></ArticleIdList></Reference><Reference><Citation>Akki R., Fath N., Mohti H. COVID-19: Oxidative Preconditioning as a Potential Therapeutic Approach. ACS Chem. Neurosci. 2020;11:3732&#x2013;3740. doi: 10.1021/acschemneuro.0c00453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00453</ArticleId><ArticleId IdType="pubmed">33147964</ArticleId></ArticleIdList></Reference><Reference><Citation>Albayda J., Mammen A.L. Is statin-induced myositis part of the polymyositis disease spectrum? Curr. Rheumatol. Rep. 2014;16:433. doi: 10.1007/s11926-014-0433-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-014-0433-8</ArticleId><ArticleId IdType="pubmed">24996782</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawasaki E., Fukuyama T., Kuriyama E., Uchida A., Sagara Y., Tamai H., Nakano Y., Tojikubo M., Koga N. Statin-induced autoimmune hepatitis in patients with type 1 diabetes: A report of two cases and literature review. J. Diabetes Investig. 2020;11:1673&#x2013;1676. doi: 10.1111/jdi.13271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdi.13271</ArticleId><ArticleId IdType="pmc">PMC7610114</ArticleId><ArticleId IdType="pubmed">32277861</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah J., Lingiah V., Pyrsopoulos N., Galan M. Acute Liver Injury in a Patient Treated with Rosuvastatin: A Rare Adverse Effect. Gastroenterol. Res. 2019;12:263&#x2013;266. doi: 10.14740/gr1212.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/gr1212</ArticleId><ArticleId IdType="pmc">PMC6785286</ArticleId><ArticleId IdType="pubmed">31636777</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez M., Castiella A., Zapata E., Zubiaurre L., Perez-Yeboles J., Mendibil L., Iribarren A. Autoimmune Hepatitis (Immune-Mediated Liver Injury) Induced By Rosuvastatin. Gastroenterol. Hepatol. 2018;41:311&#x2013;313. doi: 10.1016/j.gastrohep.2017.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gastrohep.2017.05.010</ArticleId><ArticleId IdType="pubmed">28655408</ArticleId></ArticleIdList></Reference><Reference><Citation>Clarke A.T., Johnson P.C., Hall G.C., Ford I., Mills P.R. High Dose Atorvastatin Associated with Increased Risk of Significant Hepatotoxicity in Comparison to Simvastatin in UK GPRD Cohort. PLoS ONE. 2016;11:e0151587. doi: 10.1371/journal.pone.0151587.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0151587</ArticleId><ArticleId IdType="pmc">PMC4794178</ArticleId><ArticleId IdType="pubmed">26983033</ArticleId></ArticleIdList></Reference><Reference><Citation>de Jong H.J., Tervaert J.W., Saldi S.R., Vandebriel R.J., Souverein P.C., Meyboom R.H., van Loveren H., Klungel O.H. Association between statin use and lupus-like syndrome using spontaneous reports. Semin. Arthritis Rheum. 2011;41:373&#x2013;381. doi: 10.1016/j.semarthrit.2011.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2011.06.002</ArticleId><ArticleId IdType="pubmed">21868063</ArticleId></ArticleIdList></Reference><Reference><Citation>Niklas K., Niklas A., Puszczewicz M., Wolska-Bulach A., Tykarski A. Polymyositis induced by atorvastatin. Kardiol. Pol. 2015;73:1336. doi: 10.5603/KP.2015.0246.</Citation><ArticleIdList><ArticleId IdType="doi">10.5603/KP.2015.0246</ArticleId><ArticleId IdType="pubmed">26727674</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanth R., Shah M.S., Flores R.M. Statin-associated polymyositis following omeprazole treatment. Clin. Med. Res. 2013;11:91&#x2013;95. doi: 10.3121/cmr.2012.1110.</Citation><ArticleIdList><ArticleId IdType="doi">10.3121/cmr.2012.1110</ArticleId><ArticleId IdType="pmc">PMC3692388</ArticleId><ArticleId IdType="pubmed">23580790</ArticleId></ArticleIdList></Reference><Reference><Citation>Gras-Champel V., Masmoudi I., Batteux B., Merle P.E., Liabeuf S., Masmoudi K. Statin-associated myasthenia: A case report and literature review. Therapie. 2020;75:301&#x2013;309. doi: 10.1016/j.therap.2019.07.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.therap.2019.07.004</ArticleId><ArticleId IdType="pubmed">31477339</ArticleId></ArticleIdList></Reference><Reference><Citation>Gale J., Danesh-Meyer H.V. Statins can induce myasthenia gravis. J. Clin. Neurosci. 2014;21:195&#x2013;197. doi: 10.1016/j.jocn.2013.11.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jocn.2013.11.009</ArticleId><ArticleId IdType="pubmed">24433954</ArticleId></ArticleIdList></Reference><Reference><Citation>Visconti M.J., Bashyam A.M., Jorizzo J.L. Statin-induced dermatomyositis for the practicing dermatologist: A review of the literature. Int. J. Dermatol. 2020;59:383&#x2013;387. doi: 10.1111/ijd.14751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijd.14751</ArticleId><ArticleId IdType="pubmed">31840246</ArticleId></ArticleIdList></Reference><Reference><Citation>Tutal E., Ozaras R., Leblebicioglu H. Systematic review of COVID-19 and autoimmune thyroiditis. Travel Med. Infect. Dis. 2022;47:102314. doi: 10.1016/j.tmaid.2022.102314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2022.102314</ArticleId><ArticleId IdType="pmc">PMC8930178</ArticleId><ArticleId IdType="pubmed">35307540</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight J.S., Caricchio R., Casanova J.L., Combes A.J., Diamond B., Fox S.E., Hanauer D.A., James J.A., Kanthi Y., Ladd V., et al. The intersection of COVID-19 and autoimmunity. J. Clin. Investig. 2021;131:e154886. doi: 10.1172/JCI154886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI154886</ArticleId><ArticleId IdType="pmc">PMC8670833</ArticleId><ArticleId IdType="pubmed">34710063</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A., Muller S., Kanduc D., David P., Halpert G., Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun. Rev. 2021;20:102792. doi: 10.1016/j.autrev.2021.102792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102792</ArticleId><ArticleId IdType="pmc">PMC7892316</ArticleId><ArticleId IdType="pubmed">33610751</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta M., Weaver D.F. COVID-19 as a Trigger of Brain Autoimmunity. ACS Chem. Neurosci. 2021;12:2558&#x2013;2561. doi: 10.1021/acschemneuro.1c00403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.1c00403</ArticleId><ArticleId IdType="pubmed">34213312</ArticleId></ArticleIdList></Reference><Reference><Citation>Kabacam G., Wahlin S., Efe C. Autoimmune hepatitis triggered by COVID-19: A report of two cases. Liver Int. 2021;41:2527&#x2013;2528. doi: 10.1111/liv.15044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.15044</ArticleId><ArticleId IdType="pmc">PMC8662284</ArticleId><ArticleId IdType="pubmed">34478591</ArticleId></ArticleIdList></Reference><Reference><Citation>Monton Rodriguez C., Navarro Cortes P., Lluch Garcia P., Minguez Perez M. Autoimmune hepatitis triggered by COVID-19. Rev. Esp. Enferm. Dig. 2022;114:64&#x2013;65. doi: 10.17235/reed.2021.8045/2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.17235/reed.2021.8045/2021</ArticleId><ArticleId IdType="pubmed">34015933</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalakas M.C. Guillain-Barre syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. Neurol. Neuroimmunol. Neuroinflamm. 2020;7:e781. doi: 10.1212/NXI.0000000000000781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/NXI.0000000000000781</ArticleId><ArticleId IdType="pmc">PMC7309518</ArticleId><ArticleId IdType="pubmed">32518172</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas M., Rodriguez Y., Acosta-Ampudia Y., Monsalve D.M., Zhu C., Li Q.Z., Ramirez-Santana C., Anaya J.M. Autoimmunity is a hallmark of post-COVID syndrome. J. Transl. Med. 2022;20:129. doi: 10.1186/s12967-022-03328-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12967-022-03328-4</ArticleId><ArticleId IdType="pmc">PMC8924736</ArticleId><ArticleId IdType="pubmed">35296346</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta-Ampudia Y., Monsalve D.M., Rojas M., Rodriguez Y., Zapata E., Ramirez-Santana C., Anaya J.M. Persistent Autoimmune Activation and Proinflammatory State in Post-COVID Syndrome. J. Infect. Dis. 2022;225:2155&#x2013;2162. doi: 10.1093/infdis/jiac017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac017</ArticleId><ArticleId IdType="pmc">PMC8903340</ArticleId><ArticleId IdType="pubmed">35079804</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinestel K., Czech A., Hackenbroch C., Bloch W., Gagiannis D. Clinical, radiological, and histopathological features of pulmonary post-COVID syndrome: A form of autoimmune-mediated interstitial lung disease? Pathologe. 2021;42:160&#x2013;164. doi: 10.1007/s00292-021-01024-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00292-021-01024-6</ArticleId><ArticleId IdType="pmc">PMC8631553</ArticleId><ArticleId IdType="pubmed">34850268</ArticleId></ArticleIdList></Reference><Reference><Citation>Blagova O.V., Kogan E.A., Lutokhina Y.A., Kukleva A.D., Ainetdinova D.H., Novosadov V.M., Rud R.S., Zaitsev A.Y., Zaidenov V.A., Kupriyanova A.G., et al. Subacute and chronic post-covid myoendocarditis: Clinical presentation, role of coronavirus persistence and autoimmune mechanisms. Kardiologiia. 2021;61:11&#x2013;27. doi: 10.18087/cardio.2021.6.n1659.</Citation><ArticleIdList><ArticleId IdType="doi">10.18087/cardio.2021.6.n1659</ArticleId><ArticleId IdType="pubmed">34311684</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y., Yuan D., Chen D.G., Ng R.H., Wang K., Choi J., Li S., Hong S., Zhang R., Xie J., et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185:881&#x2013;895.e20. doi: 10.1016/j.cell.2022.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.014</ArticleId><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Page E., McCallister L.P. Quantitative electron microscopic description of heart muscle cells. Application to normal, hypertrophied and thyroxin-stimulated hearts. Am. J. Cardiol. 1973;31:172&#x2013;181. doi: 10.1016/0002-9149(73)91030-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0002-9149(73)91030-8</ArticleId><ArticleId IdType="pubmed">4265518</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton D.J. Mechanisms of disease: Is mitochondrial function altered in heart failure? Methodist. Debakey Cardiovasc. J. 2013;9:44&#x2013;48. doi: 10.14797/mdcj-9-1-44.</Citation><ArticleIdList><ArticleId IdType="doi">10.14797/mdcj-9-1-44</ArticleId><ArticleId IdType="pmc">PMC3600884</ArticleId><ArticleId IdType="pubmed">23519321</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortensen S.A., Leth A., Agner E., Rohde M. Dose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol. Asp. Med. 1997;18((Suppl. 1)):S137&#x2013;S144. doi: 10.1016/S0098-2997(97)00014-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0098-2997(97)00014-9</ArticleId><ArticleId IdType="pubmed">9266515</ArticleId></ArticleIdList></Reference><Reference><Citation>Godoy J.C., Niesman I.R., Busija A.R., Kassan A., Schilling J.M., Schwarz A., Alvarez E.A., Dalton N.D., Drummond J.C., Roth D.M., et al. Atorvastatin, but not pravastatin, inhibits cardiac Akt/mTOR signaling and disturbs mitochondrial ultrastructure in cardiac myocytes. FASEB J. 2018;33:1209&#x2013;1225. doi: 10.1096/fj.201800876R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201800876R</ArticleId><ArticleId IdType="pmc">PMC6988843</ArticleId><ArticleId IdType="pubmed">30169110</ArticleId></ArticleIdList></Reference><Reference><Citation>Greene S.J., Vaduganathan M., Lupi L., Ambrosy A.P., Mentz R.J., Konstam M.A., Nodari S., Subacius H.P., Fonarow G.C., Bonow R.O., et al. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial) Am. J. Cardiol. 2013;111:574&#x2013;581. doi: 10.1016/j.amjcard.2012.10.042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2012.10.042</ArticleId><ArticleId IdType="pubmed">23206923</ArticleId></ArticleIdList></Reference><Reference><Citation>Frohlich H., Raman N., Tager T., Schellberg D., Goode K.M., Kazmi S., Grundtvig M., Hole T., Cleland J.G.F., Katus H.A., et al. Statins attenuate but do not eliminate the reverse epidemiology of total serum cholesterol in patients with non-ischemic chronic heart failure. Int. J. Cardiol. 2017;238:97&#x2013;104. doi: 10.1016/j.ijcard.2017.03.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2017.03.028</ArticleId><ArticleId IdType="pubmed">28342630</ArticleId></ArticleIdList></Reference><Reference><Citation>Dale K.M., White C.M., Henyan N.N., Kluger J., Coleman C.I. Impact of statin dosing intensity on transaminase and creatine kinase. Am. J. Med. 2007;120:706&#x2013;712. doi: 10.1016/j.amjmed.2006.07.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2006.07.033</ArticleId><ArticleId IdType="pubmed">17679130</ArticleId></ArticleIdList></Reference><Reference><Citation>Averbukh L.D., Turshudzhyan A., Wu D.C., Wu G.Y. Statin-induced Liver Injury Patterns: A Clinical Review. J. Clin. Transl. Hepatol. 2022;10:543&#x2013;552. doi: 10.14218/JCTH.2021.00271.</Citation><ArticleIdList><ArticleId IdType="doi">10.14218/JCTH.2021.00271</ArticleId><ArticleId IdType="pmc">PMC9240239</ArticleId><ArticleId IdType="pubmed">35836753</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolosa L., Carmona A., Castell J.V., Gomez-Lechon M.J., Donato M.T. High-content screening of drug-induced mitochondrial impairment in hepatic cells: Effects of statins. Arch. Toxicol. 2015;89:1847&#x2013;1860. doi: 10.1007/s00204-014-1334-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00204-014-1334-3</ArticleId><ArticleId IdType="pubmed">25160661</ArticleId></ArticleIdList></Reference><Reference><Citation>Roshanshad R., Roshanshad A., Fereidooni R., Hosseini-Bensenjan M. COVID-19 and liver injury: Pathophysiology, risk factors, outcome and management in special populations. World J. Hepatol. 2023;15:441&#x2013;459. doi: 10.4254/wjh.v15.i4.441.</Citation><ArticleIdList><ArticleId IdType="doi">10.4254/wjh.v15.i4.441</ArticleId><ArticleId IdType="pmc">PMC10190688</ArticleId><ArticleId IdType="pubmed">37206656</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbari H., Taghizadeh-Hesary F. COVID-19 induced liver injury from a new perspective: Mitochondria. Mitochondrion. 2023;70:103&#x2013;110. doi: 10.1016/j.mito.2023.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mito.2023.04.001</ArticleId><ArticleId IdType="pmc">PMC10088285</ArticleId><ArticleId IdType="pubmed">37054906</ArticleId></ArticleIdList></Reference><Reference><Citation>Helou M., Nasr J., El Osta N., Jabbour E., Husni R. Liver manifestations in COVID-19 patients: A review article. World J. Clin. Cases. 2023;11:2189&#x2013;2200. doi: 10.12998/wjcc.v11.i10.2189.</Citation><ArticleIdList><ArticleId IdType="doi">10.12998/wjcc.v11.i10.2189</ArticleId><ArticleId IdType="pmc">PMC10131011</ArticleId><ArticleId IdType="pubmed">37122526</ArticleId></ArticleIdList></Reference><Reference><Citation>Martini N., Singla P., Arbuckle E., Goyal G., Liu Q., Santos-Zabala M.L., Zainah H. SARS-CoV-2-Induced Autoimmune Hepatitis. Cureus. 2023;15:e38932. doi: 10.7759/cureus.38932.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.38932</ArticleId><ArticleId IdType="pmc">PMC10257862</ArticleId><ArticleId IdType="pubmed">37309335</ArticleId></ArticleIdList></Reference><Reference><Citation>Durazzo M., Ferro A. SARS-CoV-2 and autoimmune hepatitis onset: A new association. Minerva Gastroenterol. 2022;68:259&#x2013;260. doi: 10.23736/S2724-5985.22.03167-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S2724-5985.22.03167-9</ArticleId><ArticleId IdType="pubmed">36083103</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller W.L. Steroid hormone synthesis in mitochondria. Mol. Cell Endocrinol. 2013;379:62&#x2013;73. doi: 10.1016/j.mce.2013.04.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mce.2013.04.014</ArticleId><ArticleId IdType="pubmed">23628605</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyyppa M.T., Kronholm E., Virtanen A., Leino A., Jula A. Does simvastatin affect mood and steroid hormone levels in hypercholesterolemic men? A randomized double-blind trial. Psychoneuroendocrinology. 2003;28:181&#x2013;194. doi: 10.1016/S0306-4530(02)00014-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4530(02)00014-8</ArticleId><ArticleId IdType="pubmed">12510011</ArticleId></ArticleIdList></Reference><Reference><Citation>Schooling C.M., Au Yeung S.L., Freeman G., Cowling B.J. The effect of statins on testosterone in men and women, a systematic review and meta-analysis of randomized controlled trials. BMC Med. 2013;11:57. doi: 10.1186/1741-7015-11-57.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-11-57</ArticleId><ArticleId IdType="pmc">PMC3621815</ArticleId><ArticleId IdType="pubmed">23448151</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobs A.S., Schrott H., Davidson M.H., Bays H., Stein E.A., Kush D., Wu M., Mitchel Y., Illingworth R.D. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism. 2000;49:1234&#x2013;1238. doi: 10.1053/meta.2000.7716a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/meta.2000.7716a</ArticleId><ArticleId IdType="pubmed">11016911</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohamed M.S., Moulin T.C., Schioth H.B. Sex differences in COVID-19: The role of androgens in disease severity and progression. Endocrine. 2021;71:3&#x2013;8. doi: 10.1007/s12020-020-02536-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12020-020-02536-6</ArticleId><ArticleId IdType="pmc">PMC7657570</ArticleId><ArticleId IdType="pubmed">33179220</ArticleId></ArticleIdList></Reference><Reference><Citation>Pegiou S., Rentzeperi E., Koufakis T., Metallidis S., Kotsa K. The role of sexual dimorphism in susceptibility to SARS-CoV-2 infection, disease severity, and mortality: Facts, controversies and future perspectives. Microbes Infect. 2021;23:104850. doi: 10.1016/j.micinf.2021.104850.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2021.104850</ArticleId><ArticleId IdType="pmc">PMC8196472</ArticleId><ArticleId IdType="pubmed">34129909</ArticleId></ArticleIdList></Reference><Reference><Citation>Golomb B.A. Higher LDL and Lesser LDL-Drop Linked to More Muscle Problems in Men on Statins. Circulation. 2013;127:AP073.</Citation></Reference><Reference><Citation>Linares L., Golomb B., Jaojoco J., Sikand H., Phillips P.S. The Modern Spectrum of Rhabdomyolysis: Drug Toxicity Revealed by Creatine Kinase Screening. Curr. Drug Saf. 2009;4:181&#x2013;187. doi: 10.2174/157488609789007010.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157488609789007010</ArticleId><ArticleId IdType="pubmed">19534642</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., Cao J., Yu Y., Ding J., Eshak E.S., Liu K., Mubarik S., Shi F., Wen H., Zeng Z., et al. Epidemiological characteristics of patients with severe COVID-19 infection in Wuhan, China: Evidence from a retrospective observational study. Int. J. Epidemiol. 2020;49:1940&#x2013;1950. doi: 10.1093/ije/dyaa180.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyaa180</ArticleId><ArticleId IdType="pmc">PMC7665537</ArticleId><ArticleId IdType="pubmed">33150437</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiggins B.S., Saseen J.J., Page R.L., 2nd, Reed B.N., Sneed K., Kostis J.B., Lanfear D., Virani S., Morris P.B. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2016;134:e468&#x2013;e495. doi: 10.1161/CIR.0000000000000456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIR.0000000000000456</ArticleId><ArticleId IdType="pubmed">27754879</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin M., Tong Q. Rhabdomyolysis as potential late complication associated with 2019 novel coronavirus disease. Emerg. Infect. Dis. 2020;26:1618&#x2013;1620. doi: 10.3201/eid2607.200445.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2607.200445</ArticleId><ArticleId IdType="pmc">PMC7323559</ArticleId><ArticleId IdType="pubmed">32197060</ArticleId></ArticleIdList></Reference><Reference><Citation>Fadila M.F., Wool K.J. Rhabdomyolysis secondary to influenza a infection: A case report and review of the literature. N. Am. J. Med. Sci. 2015;7:122&#x2013;124. doi: 10.4103/1947-2714.153926.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/1947-2714.153926</ArticleId><ArticleId IdType="pmc">PMC4382767</ArticleId><ArticleId IdType="pubmed">25839005</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh U., Scheld W.M. Infectious etiologies of rhabdomyolysis: Three case reports and review. Clin. Infect. Dis. 1996;22:642&#x2013;649. doi: 10.1093/clinids/22.4.642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/clinids/22.4.642</ArticleId><ArticleId IdType="pubmed">8729203</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan P., Saha B. Metabolic regulation of infection and inflammation. Cytokine. 2018;112:1&#x2013;11. doi: 10.1016/j.cyto.2018.11.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2018.11.016</ArticleId><ArticleId IdType="pubmed">30472107</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganji R., Reddy P.H. Impact of COVID-19 on Mitochondrial-Based Immunity in Aging and Age-Related Diseases. Front. Aging Neurosci. 2020;12:614650. doi: 10.3389/fnagi.2020.614650.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2020.614650</ArticleId><ArticleId IdType="pmc">PMC7835331</ArticleId><ArticleId IdType="pubmed">33510633</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali L., Mohammed I., Janjua I., Naeem M., Adeli G., Elalamy O., Alhatou M., Akhtar N., Canibano B., Iqrar A. Acute Myocardial Injury and Rhabdomyolysis in COVID-19 Patients: Incidence and Mortality. Cureus. 2021;13:e18899. doi: 10.7759/cureus.18899.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.18899</ArticleId><ArticleId IdType="pmc">PMC8599434</ArticleId><ArticleId IdType="pubmed">34804738</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroun M.W., Dieiev V., Kang J., Barbi M., Marashi Nia S.F., Gabr M., Eman G., Kajita G., Swedish K. Rhabdomyolysis in COVID-19 Patients: A Retrospective Observational Study. Cureus. 2021;13:e12552. doi: 10.7759/cureus.12552.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.12552</ArticleId><ArticleId IdType="pmc">PMC7869906</ArticleId><ArticleId IdType="pubmed">33575135</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis R., Graves J., Horton L.E., Lee S.J., Liang N.-C., Minassian A., Phreaner N., Wang A. COVID-19 for the Long Haul: Symposium on Post COVID Recovery and Care; Proceedings of the CME Symposium; Online. 26 February 2022.</Citation></Reference><Reference><Citation>Twomey R., DeMars J., Franklin K., Culos-Reed S.N., Weatherald J., Wrightson J.G. Chronic Fatigue and Postexertional Malaise in People Living with Long COVID: An Observational Study. Phys. Ther. 2022;102:pzac005. doi: 10.1093/ptj/pzac005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ptj/pzac005</ArticleId><ArticleId IdType="pmc">PMC9383197</ArticleId><ArticleId IdType="pubmed">35079817</ArticleId></ArticleIdList></Reference><Reference><Citation>Stallmach A., Kesselmeier M., Bauer M., Gramlich J., Finke K., Fischer A., Fleischmann-Struzek C., Heutelbeck A., Katzer K., Mutschke S., et al. Comparison of fatigue, cognitive dysfunction and psychological disorders in post-COVID patients and patients after sepsis: Is there a specific constellation? Infection. 2022;50:661&#x2013;669. doi: 10.1007/s15010-021-01733-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01733-3</ArticleId><ArticleId IdType="pmc">PMC8741139</ArticleId><ArticleId IdType="pubmed">34997542</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceban F., Ling S., Lui L.M.W., Lee Y., Gill H., Teopiz K.M., Rodrigues N.B., Subramaniapillai M., Di Vincenzo J.D., Cao B., et al. Fatigue and cognitive impairment in Post-COVID-19 Syndrome: A systematic review and meta-analysis. Brain Behav. Immun. 2022;101:93&#x2013;135. doi: 10.1016/j.bbi.2021.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.020</ArticleId><ArticleId IdType="pmc">PMC8715665</ArticleId><ArticleId IdType="pubmed">34973396</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillips P.S., Haas R.H., Bannykh S., Hathaway S., Gray N.L., Kimura B.J., Vladutiu G.D., England J.D. Statin-associated myopathy with normal creatine kinase levels. Ann. Intern. Med. 2002;137:581&#x2013;585. doi: 10.7326/0003-4819-137-7-200210010-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-137-7-200210010-00009</ArticleId><ArticleId IdType="pubmed">12353945</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam M.S., Czajkowsky D.M. SARS-CoV-2 infection and oxidative stress: Pathophysiological insight into thrombosis and therapeutic opportunities. Cytokine Growth Factor. Rev. 2022;63:44&#x2013;57. doi: 10.1016/j.cytogfr.2021.11.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2021.11.001</ArticleId><ArticleId IdType="pmc">PMC8591899</ArticleId><ArticleId IdType="pubmed">34836751</ArticleId></ArticleIdList></Reference><Reference><Citation>Fodor A., Tiperciuc B., Login C., Orasan O.H., Lazar A.L., Buchman C., Hanghicel P., Sitar-Taut A., Suharoschi R., Vulturar R., et al. Endothelial Dysfunction, Inflammation, and Oxidative Stress in COVID-19-Mechanisms and Therapeutic Targets. Oxid. Med. Cell. Longev. 2021;2021:8671713. doi: 10.1155/2021/8671713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/8671713</ArticleId><ArticleId IdType="pmc">PMC8397545</ArticleId><ArticleId IdType="pubmed">34457119</ArticleId></ArticleIdList></Reference><Reference><Citation>Forcados G.E., Muhammad A., Oladipo O.O., Makama S., Meseko C.A. Metabolic Implications of Oxidative Stress and Inflammatory Process in SARS-CoV-2 Pathogenesis: Therapeutic Potential of Natural Antioxidants. Front. Cell Infect. Microbiol. 2021;11:654813. doi: 10.3389/fcimb.2021.654813.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2021.654813</ArticleId><ArticleId IdType="pmc">PMC8188981</ArticleId><ArticleId IdType="pubmed">34123871</ArticleId></ArticleIdList></Reference><Reference><Citation>Chernyak B.V., Popova E.N., Prikhodko A.S., Grebenchikov O.A., Zinovkina L.A., Zinovkin R.A. COVID-19 and Oxidative Stress. Biochemistry. 2020;85:1543&#x2013;1553. doi: 10.1134/S0006297920120068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S0006297920120068</ArticleId><ArticleId IdType="pmc">PMC7768996</ArticleId><ArticleId IdType="pubmed">33705292</ArticleId></ArticleIdList></Reference><Reference><Citation>Pliss A., Kuzmin A.N., Prasad P.N., Mahajan S.D. Mitochondrial Dysfunction: A Prelude to Neuropathogenesis of SARS-CoV-2. ACS Chem. Neurosci. 2022;13:308&#x2013;312. doi: 10.1021/acschemneuro.1c00675.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.1c00675</ArticleId><ArticleId IdType="pmc">PMC8790819</ArticleId><ArticleId IdType="pubmed">35049274</ArticleId></ArticleIdList></Reference><Reference><Citation>Ajaz S., McPhail M.J., Singh K.K., Mujib S., Trovato F.M., Napoli S., Agarwal K. Mitochondrial metabolic manipulation by SARS-CoV-2 in peripheral blood mononuclear cells of patients with COVID-19. Am. J. Physiol. Cell Physiol. 2021;320:C57&#x2013;C65. doi: 10.1152/ajpcell.00426.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpcell.00426.2020</ArticleId><ArticleId IdType="pmc">PMC7816428</ArticleId><ArticleId IdType="pubmed">33151090</ArticleId></ArticleIdList></Reference><Reference><Citation>Wieczfinska J., Kleniewska P., Pawliczak R. Oxidative Stress-Related Mechanisms in SARS-CoV-2 Infections. Oxid. Med. Cell. Longev. 2022;2022:5589089. doi: 10.1155/2022/5589089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/5589089</ArticleId><ArticleId IdType="pmc">PMC8906126</ArticleId><ArticleId IdType="pubmed">35281470</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagstaff L.R., Mitton M.W., Arvik B.M., Doraiswamy P.M. Statin-associated memory loss: Analysis of 60 case reports and review of the literature. Pharmacotherapy. 2003;23:871&#x2013;880. doi: 10.1592/phco.23.7.871.32720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1592/phco.23.7.871.32720</ArticleId><ArticleId IdType="pubmed">12885101</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration . FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol-Lowering Statin Drugs. U.S. Food and Drug Administration; Silver Spring, MD, USA: 2012.</Citation></Reference><Reference><Citation>Chatham K., Gelder C.M., Lines T.A., Cahalin L.P. Suspected statin-induced respiratory muscle myopathy during long-term inspiratory muscle training in a patient with diaphragmatic paralysis. Phys. Ther. 2009;89:257&#x2013;266. doi: 10.2522/ptj.20080155.</Citation><ArticleIdList><ArticleId IdType="doi">10.2522/ptj.20080155</ArticleId><ArticleId IdType="pubmed">19147707</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinicke K., Taivassalo T., Wyrick P., Wood H., Babb T.G., Haller R.G. Exertional dyspnea in mitochondrial myopathy: Clinical features and physiological mechanisms. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011;301:R873&#x2013;R884. doi: 10.1152/ajpregu.00001.2011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.00001.2011</ArticleId><ArticleId IdType="pmc">PMC3197343</ArticleId><ArticleId IdType="pubmed">21813873</ArticleId></ArticleIdList></Reference><Reference><Citation>Scharfen J., Peters J.M., Holling H. Retest effects in cognitive ability tests: A meta-analysis. Intelligence. 2018;67:44&#x2013;66. doi: 10.1016/j.intell.2018.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intell.2018.01.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Muldoon M.F., Barger S.D., Ryan C.M., Flory J.D., Lehoczky J.P., Matthews K.A., Manuck S.B. Effects of lovastatin on cognitive function and psychological well-being. Am. J. Med. 2000;108:538&#x2013;546. doi: 10.1016/S0002-9343(00)00353-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9343(00)00353-3</ArticleId><ArticleId IdType="pubmed">10806282</ArticleId></ArticleIdList></Reference><Reference><Citation>Muldoon M.F., Ryan C.M., Sereika S.M., Flory J.D., Manuck S.B. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am. J. Med. 2004;117:823&#x2013;829. doi: 10.1016/j.amjmed.2004.07.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2004.07.041</ArticleId><ArticleId IdType="pubmed">15589485</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortensen E.M., Restrepo M.I., Copeland L.A., Pugh M.J., Anzueto A. Statins and outcomes in patients with pneumonia: Not only healthy user bias. BMJ. 2006;333:1123&#x2013;1124. doi: 10.1136/bmj.39038.509167.1F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39038.509167.1F</ArticleId><ArticleId IdType="pmc">PMC1661774</ArticleId><ArticleId IdType="pubmed">17124232</ArticleId></ArticleIdList></Reference><Reference><Citation>Rundek T., Naini A., Sacco R., Coates K., DiMauro S. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. Arch. Neurol. 2004;61:889&#x2013;892. doi: 10.1001/archneur.61.6.889.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.61.6.889</ArticleId><ArticleId IdType="pubmed">15210526</ArticleId></ArticleIdList></Reference><Reference><Citation>Myhill S., Booth N.E., McLaren-Howard J. Chronic fatigue syndrome and mitochondrial dysfunction. Int. J. Clin. Exp. Med. 2009;2:1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2680051</ArticleId><ArticleId IdType="pubmed">19436827</ArticleId></ArticleIdList></Reference><Reference><Citation>Preiss D., Seshasai S.R., Welsh P., Murphy S.A., Ho J.E., Waters D.D., DeMicco D.A., Barter P., Cannon C.P., Sabatine M.S., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. J. Am. Med. Assoc. 2011;305:2556&#x2013;2564. doi: 10.1001/jama.2011.860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2011.860</ArticleId><ArticleId IdType="pubmed">21693744</ArticleId></ArticleIdList></Reference><Reference><Citation>Sattar N., Preiss D., Murray H.M., Welsh P., Buckley B.M., de Craen A.J., Seshasai S.R., McMurray J.J., Freeman D.J., Jukema J.W., et al. Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735&#x2013;742. doi: 10.1016/S0140-6736(09)61965-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(09)61965-6</ArticleId><ArticleId IdType="pubmed">20167359</ArticleId></ArticleIdList></Reference><Reference><Citation>de Almeida Ferreira M., Mendonca J.A. Long-term testosterone replacement therapy reduces fatigue in men with hypogonadism. Drugs Context. 2022;11:1&#x2013;6. doi: 10.7573/dic.2021-8-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.7573/dic.2021-8-12</ArticleId><ArticleId IdType="pmc">PMC8823386</ArticleId><ArticleId IdType="pubmed">35211178</ArticleId></ArticleIdList></Reference><Reference><Citation>Bercea R.M., Mihaescu T., Cojocaru C., Bjorvatn B. Fatigue and serum testosterone in obstructive sleep apnea patients. Clin. Respir. J. 2015;9:342&#x2013;349. doi: 10.1111/crj.12150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/crj.12150</ArticleId><ArticleId IdType="pubmed">24725752</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu G., Traish A.M. Induced testosterone deficiency: From clinical presentation of fatigue, erectile dysfunction and muscle atrophy to insulin resistance and diabetes. Horm. Mol. Biol. Clin. Investig. 2011;8:425&#x2013;430. doi: 10.1515/HMBCI.2011.131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/HMBCI.2011.131</ArticleId><ArticleId IdType="pubmed">25961342</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivas-Shankar U., Roberts S.A., Connolly M.J., O&#x2019;Connell M.D., Adams J.E., Oldham J.A., Wu F.C. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: A randomized, double-blind, placebo-controlled study. J. Clin. Endocrinol. Metab. 2010;95:639&#x2013;650. doi: 10.1210/jc.2009-1251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/jc.2009-1251</ArticleId><ArticleId IdType="pubmed">20061435</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin K.Y., Soelaiman I.N., Naina Mohamed I., Shahar S., Teng N.I., Suhana Mohd Ramli E., Ahmad F., Aminuddin A., Zurinah Wan Ngah W. Testosterone is associated with age-related changes in bone health status, muscle strength and body composition in men. Aging Male. 2012;15:240&#x2013;245. doi: 10.3109/13685538.2012.724740.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/13685538.2012.724740</ArticleId><ArticleId IdType="pubmed">23098182</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilherme J., Semenova E.A., Borisov O.V., Larin A.K., Moreland E., Generozov E.V., Ahmetov I.I. Genomic predictors of testosterone levels are associated with muscle fiber size and strength. Eur. J. Appl. Physiol. 2022;122:415&#x2013;423. doi: 10.1007/s00421-021-04851-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00421-021-04851-w</ArticleId><ArticleId IdType="pmc">PMC8783862</ArticleId><ArticleId IdType="pubmed">34792618</ArticleId></ArticleIdList></Reference><Reference><Citation>Beauchet O. Testosterone and cognitive function: Current clinical evidence of a relationship. Eur. J. Endocrinol. 2006;155:773&#x2013;781. doi: 10.1530/eje.1.02306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1530/eje.1.02306</ArticleId><ArticleId IdType="pubmed">17132744</ArticleId></ArticleIdList></Reference><Reference><Citation>Italia L., Tomasoni D., Bisegna S., Pancaldi E., Stretti L., Adamo M., Metra M. COVID-19 and Heart Failure: From Epidemiology During the Pandemic to Myocardial Injury, Myocarditis, and Heart Failure Sequelae. Front. Cardiovasc. Med. 2021;8:713560. doi: 10.3389/fcvm.2021.713560.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.713560</ArticleId><ArticleId IdType="pmc">PMC8382715</ArticleId><ArticleId IdType="pubmed">34447795</ArticleId></ArticleIdList></Reference><Reference><Citation>Marik P. EVMS Critical Care COVID-19 Management Protocol.  [(accessed on 5 August 2020)].  Available online:  https://www.evms.edu/media/evms_public/departments/internal_medicine/EVMS_Critical_Care_COVID-19_Protocol.pdf.</Citation></Reference><Reference><Citation>Castiglione V., Chiriaco M., Emdin M., Taddei S., Vergaro G. Statin therapy in COVID-19 infection. Eur. Heart J. Cardiovasc. Pharmacother. 2020;6:258&#x2013;259. doi: 10.1093/ehjcvp/pvaa042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcvp/pvaa042</ArticleId><ArticleId IdType="pmc">PMC7197622</ArticleId><ArticleId IdType="pubmed">32347925</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>